Connective tissue growth factor (CTGF) is a multifunctional matricelluar protein, playing a role as a central mediator in tissue remodeling and fibrosis. A number of reports have demonstrated the pivotal roles of CTGF in the progression of fibrosis, suggesting CTGF as a promising therapeutic target for the treatment of fibrotic disorders including hypertrophic scars and keloids.
INTRODUCTION
Connective tissue growth factor (CTGF/CCN2) is a secreted matricellular protein known to play important roles in many biological processes, including cell adhesion, migration, proliferation, angiogenesis, vascular differentiation and myofibroblast formation, all of which can lead to tissue remodeling and changes in organ structure. (Lipson et al., 2012) . One of the key functions of CTGF is controlling and coordinating signal transduction pathways involving cell surface proteoglycans, which are components of the extracellular matrix and growth factors. Overexpression of CTGF is known to be associated with the pathology of a number of fibrotic disorders such as skin fibrosis (hypertrophic scar and keloid), fibrotic liver disease, idiopathic pulmonary fibrosis, proliferative diabetic retinopathy, and diabetic kidney disease. (Gressner and Gressner, 2008; Ihn, 2002; Kono et al., 2011; Rachfal and Brigstock, 2003) In skin, collagen is the major structural protein and CTGF functions as an intrinsic, physiological mediator of collagen type I & III expression. During the wound healing process, transforming growth factor-β (TGF-β) stimulates the expression of CTGF and induces CTGF-triggered collagen production. (Colwell et al., 2005) Thus, CTGF is suggested as an important target for the treatment of hypertrophic scars and keloids, which are caused by excessive fibrosis during the wound healing process. Indeed, several studies confirmed that the inhibition of CTGF expression or activity by antisense oligonucleotides or antibodies lead to a reduction in excessive collagen deposition and the pathologic severity of fibrosis. (Sisco et al., 2008; Wang et al., 2011) M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT suppression, which is mediated by a short double-stranded RNA termed small interfering RNA (siRNA) . Intracellular delivery of siRNA leads to the inhibition of target gene expression via specific recognition and cleavage of mRNA with sequence complementarity to siRNA, catalyzed by the cellular RNAi machinery. Due to the unparalleled specificity and efficiency in target gene silencing, RNAi-mediated gene silencing is regarded as one of the most promising therapeutic development platforms against various diseases. (Carthew and Sontheimer, 2009; Dorsett and Tuschl, 2004; Elbashir et al., 2001) Despite high expectations, efficient delivery of siRNA molecules to diseased tissue or organs in vivo still remains a major obstacle to be overcome in the development of effective RNAi therapeutics. The highly negative charges of siRNA due to the phosphate backbone structure prevent siRNA from entering the cell through the plasma membrane. Therefore, it is necessary to use delivery vehicles, e.g. liposomes and nanoparticles, in order to achieve the proper tissue distribution and cellular uptake of siRNA.
Instead of using delivery vehicles, direct introduction of chemical modifications to the siRNA backbone was also attempted to improve cellular uptake. For example, several studies reported that conjugation of a cholesterol moiety to the siRNA enables the intracellular uptake of siRNA. (Soutschek et al., 2004; Wolfrum et al., 2007) In addition to its role in protecting against nuclease activity, phosphorothioate modification was reported to enhance intracellular delivery of oligonucleotides. (Connolly et al., 1984; Spitzer and Eckstein, 1988; Thierry and Dritschilo, 1992; Woolf et al., 1990; Zhao et al., 1993) Accordingly, these findings suggest that it is possible to M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT develop potent RNAi therapeutics by introducing optimal chemical modifications to the siRNA molecule.
In this study, we present the successful development of a potent RNAi triggering molecule targeting CTGF. Previously, we introduced a siRNA structure termed asymmetric siRNA (asiRNA), which had significantly mitigated off-target effects compared to conventional siRNA. (Chang et al., 2009; Hong et al., 2014; Jo et al., 2011) Based on the asiRNA backbone structure, we introduced several chemical modifications, such as cholesterol conjugation and phosphorothioate, to enhance the intracellular uptake of the RNAi triggering molecule. We also incorporated 2'-O-methyl (2'OMe) to enhance the stability of the asiRNA. The resulting RNAi trigger targeting CTGF (cp-asiCTGF) showed efficient target gene suppression activity without the need for delivery vehicles both in vitro and in vivo.
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RESULTS
Selection of a potent cp-asiRNA targeting CTGF (cp-asiCTGF)
In order to identify effective asiRNA candidates with the most potent target gene silencing effects, 40 target sequences spanning the length of the human CTGF mRNA were chosen and the corresponding asiRNAs were designed for each sequence. Based on the CTGF repression activity, asiRNA with the most potent target gene silencing activity were selected (data not shown). Then, chemical modifications were introduced to the selected asiRNAs to generate cell penetrating asiRNAs (cp-asiRNAs). The resulting cp-asiRNA targeting CTGF (cp-asiCTGF, Figure 1a ) carries chemical modifications such as cholesterol conjugation at the 3'-end of the passenger strand, phosphorothioate backbone modification, and 2'-O-Methyl modification of the ribose sugar on both strands.
Inhibition of CTGF expression by cp-asiCTGF in vitro
Target gene silencing activity for cp-asiCTGF was analyzed in the human lung adenocarcinoma A549 cells which express target gene CTGF. As shown in Fig. 1b , the transfection of CTGFtargeting RNAi triggering molecules including conventional siRNA (siCTGF), asiRNA (asiCTGF), and asiRNA with chemical modification described in Fig. 1a (cp-asiCTGF) efficiently reduced the target gene expression at the mRNA level. In detail, we observed that cp-asiCTGF has most potent target gene silencing activity between tested RNAi triggering molecules. At the concentrations tested (50 nM final), more than 85% knock-down by cp-asiCTGF was observed ( Fig. 1b ). Then, we investigated the target gene silencing activity of cp-asiCTGF without the aid of a transfection reagent. A549 cells were treated with media containing M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT siCTGF, asiCTGF, or cp-asiCTGF, and the target gene level was analyzed. We observed potent target mRNA repression by cp-asiCTGF ( Fig. 1b ). The incubation of cells with 1 µM cp-asiCTGF resulted in more than 85% knock-down of CTGF at the mRNA level. On the other hand, neither siCTGF or asiCTGF treated sample showed significant target mRNA reduction without the aid of delivering reagent. For dose response analysis, A549 cells were treated with media containing different concentrations of cp-asiCTGF and dose dependent target mRNA knockdown by cp-asiCTGF was confirmed (IC 50 = 0.315 nM, Fig. 1c ).
CTGF protein level knockdown analysis was conducted under the condition of transforming growth factor β (TGF-β) induction. CTGF mRNA in A549 cells is detectable in northern blot analysis in previous study (Hishikawa et al., 1999a) and we also observed modest expression of CTGF mRNA level in the present study. In detail, real-time PCR raw data reported cycle threshold (C T ) value for CTGF was about 26.5. However, CTGF protein is known to merely detectable in A549 cell lysate (Chang et al., 2004) attributed from the nature of the protein as a secreted protein. TGF-β treatment is known to induce expression of CTGF (Hishikawa et al., 1999b; Hishikawa et al., 1999c) and we observed induction of CTGF mRNA and protein expression in the presence of TGF-β in A549 cells (Figure 2a , b). In this condition, cp-asiCTGF treatment reduced the expression of the target mRNA and protein as well in a dose-dependent manner (Figure 2a (Khoo et al., 2006) . Thus, it is expected that potent RNAi triggers targeting CTGF could be developed as therapeutics for keloid treatment. We observed high basal level expression of CTGF in the KEL FIB cells, which was efficiently reduced by cp-asiCTGF treatment ( Figure   2c ).
In vivo examination of cp-asiCTGF target gene silencing activity
As the next step, in vivo analysis of cp-asiCTGF was conducted. Several studies describe target gene knockdown by intradermal injection of oligonucleotides without aid of delivering reagents in rat skin (Sisco et al., 2008; Karen et al, 2014) . In addition to the animal studies, dose range from sub-milligram to milligrams per injection was suggested from human clinical trials design (NCT02030275 and NCT01037985). We examined target gene silencing by cp-asiCTGF intradermal injection with different doses in rat skin. Four different amount of cp-asiCTGF ranging from 0.1 to 1 mg were injected into rat skin and, after 24 hours, skin biopsy samples were collected from the injection sites and subjected to qRT-PCR analysis in order to assess the mRNA level of CTGF. The analysis showed that the intradermal injection of cp-asiCTGF led to potent target gene silencing in dose dependent manner ( Figure 3a ). On the other hand, SC cp-asiCTGF (cp-asiRNA with a scrambled sequence used as the negative control) did not reduce CTGF mRNA level at 1 mg injection condition ( Figure 3a ). The specific knockdown by cp-asiCTGF was also confirmed in target protein analysis after 72 hours of intradermal injection. As shown in Figure 3b , significant reduction of CTGF protein was observed in cp-asiCTGF-treated samples compared to the scrambled cp-asiRNA-treated samples (SC cp-asiCTGF). To visualize cp-asiCTGF distribution after intradermal injection, rat skin was intradermally injected with Cy5.5labeled cp-asiCTGF, and its distribution was analyzed by laser confocal scanning microscopy.
The result showed extensive distribution of fluorescent signals at the site of injection (Figure 3c ), suggesting the efficient delivery of cp-asiRNA into cells, followed by potent target gene silencing in vivo. We also compared in vivo target gene silencing activity of cp-asiCTGF with commercially available self-delivery siRNA ( Figure S1 ). The results showed that the cp-asiCTGF have higher target gene silencing potency than the commercially available siRNA in both mRNA and protein level. In detail, compared to the commercially available siRNA, cp-asiCTGF showed similar or higher level of target gene knockdown in 10-fold lower dose.
Effect of cp-asiCTGF on rat skin excision wound model
We further investigated the in vivo effects of cp-asiCTGF in the rat skin excision wound model.
Consistent with its key roles in fibrosis, CTGF is known to be up-regulated at wound sites in the excision wound model (Mori et al., 2002; Sisco et al., 2008) . After the establishment of excision wounds (Day 0), cp-asiCTGF or SC cp-asiCTGF was treated via intradermal injection on Days 14, 18, 22 and 26. On Day 29, skin samples were collected and subjected to further analysis. We exploited qRT-PCR analysis to measure CTGF mRNA and western blot and immunohistochemistry analysis to measure CTGF protein. At the time of harvest, the level of CTGF mRNA in the cp-asiCTGF treated samples was reduced by about 80% in comparison to saline treated samples while the SC cp-asiCTGF did not show any effect on the level of CTGF mRNA (Figure 4a ). We also examined the expression of rat collagen type I and III at the mRNA level. Consistent with the change in CTGF mRNA, the levels of collagen type I and III mRNA were also reduced in cp-asiCTGF treated samples (Figure 4b The decrease in CTGF and collagen type I proteins was also observed by immunohistochemistry analysis in tissue sections of skin treated with cp-asiCTGF (Figure 5a, b, c, d , e and f). As shown in figure 5a and 5b, intradermal injection of cp-asiCTGF resulted in a reduction in CTGF protein staining in comparison to the saline treated control in the dermis at the wound sites. Injection of SC cp-asiCTGF, however, was not resulted in target protein reduction (Figure 5c and j).
Immunohistochemistry analysis for collagen type I also demonstrated effective reduction of the collagen type I level by cp-asiCTGF administration at the dermis (Figure 5d , e, f and k). In addition, the sectioned skin samples were stained with Masson's Trichrome staining (MTS) to confirm the collagen levels in excision wound skin (Figure 5g , h and i). In saline treated samples, markedly increased collagen deposition at the excision site was observed compared to surrounding normal tissue (Figure 5g ). In contrast, cp-asiCTGF treated skin showed a reduced level of collagen at the excision site while the control siRNA (SC cp-asiCTGF) did not affect level of collagen (Figure 5g , h, i and l).
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DISCUSSION
In this study, we developed cp-asiRNA, an RNAi trigger platform with cell membrane penetrating capability. This RNAi trigger is structurally based on asymmetric siRNA with a shortened passenger strand (16 nt), which shows reduced nonspecific effects compared to conventional siRNA (Chang et al., 2009; Hong et al., 2014; Jo et al., 2011) . In addition, cp-asiRNA has chemical modifications including cholesterol conjugation, phosphorothioate (PS) modification and 2'-O-metyl (2'-OMe) modification. PS modification is known to increase endocytosis as well as to improve serum stability (Ge et al., 2010) . Nucleic acids conjugated with cholesterol interact with the membranes of cells and enhance cellular uptake (Soutschek et al., 2004; Wolfrum et al., 2007) . 2'-OMe modification to RNA has been shown to increase siRNA stability against endonucleases and reduce immune stimulation (Burnett and Rossi, 2012) . We confirmed that the cp-asiRNA harboring these modifications exhibited potent target gene silencing ability without the aid of delivery vehicles, suggesting that the cp-asiRNA is a potent RNAi trigger compound that can be developed for RNAi therapeutics.
Using the cp-asiRNA targeting CTGF, we showed efficient in vitro and in vivo target gene silencing. We also examined the effect of cp-asiCTGF treatment in a rat skin excision wound model and the results demonstrated potent CTGF gene silencing along with a reduced level of fibrosis. We expect that the cp-asiCTGF compound has great potential to be further developed into therapeutics for treating skin fibrotic disorders including hypertrophic scars and keloids.
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MATERIALS AND METHODS siRNAs
Chemically synthesized, high-performance liquid chromatography-purified RNAs were purchased from STpharm (Seoul, South Korea) and annealed according to the manufacturer's instructions. Sequence information for each RNA is provided in Table S1 .
Transfection and treatment of siRNAs
A549, HaCaT, HeLa and KEL FIB cells were purchased from ATCC and maintained at 37 ºC in Dulbecco's modified Eagle's medium (Invitrogen, Calsbad, CA) supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were routinely subcultured to maintain exponential growth. For transfection, cells were plated on 12-well plates 24 hours before transfection at 30%-50% confluence in complete medium. Lipofectamine 2000 was used for transfection following the manufacturer's protocol (Invitrogen). Cells were harvested 24 hours after transfection for further analysis. For the treatment of siRNAs without transfection reagent, cells were plated in 12-well plates at 30-50% confluence in complete medium. After 24 hours, cells were washed with 1xDPBS (Gibco) and incubated for 4 hours in Opti-MEM containing siRNA. Then the siRNA-containing Opti-MEM media was replaced with serum containing complete media. After 24 hours or 48 hours, further analysis was conducted including target gene expression analysis. For TGF-β induction, cells were treated with 2ng/ml TGF-β (R&D Systems, Minneapolis, MN) in serum containing complete media for 24hours.
Quantitative real-time polymerase chain reaction
Total RNA were extracted using RNAiPlus ® (TaKaRa) and then 0.5 µg of total RNA was used for cDNA synthesis using the High-capacity cDNA reverse transcription kit (Applied Biosystems) protease inhibitor cocktail (Roche). The protein concentration was measured using a Bradford assay kit. Equal amounts of protein were resolved via SDS-PAGE gel electrophoresis. After electrophoresis, the proteins were transferred to PVDF membrane (Bio-rad) already activated by methanol (Merck) for 1 hour. The membrane was blocked for 1 hour at room temperature with 5% skim milk and then incubated overnight at 4 ºC in 5% skim milk containing specific antibodies (Anti-CTGF antibody: Novus and Santa cruz, anti-β-Actin antibody: Santa cruz, anti-GAPDH antibody: Santa cruz, anti-HSP90 antibody: Novus). The membrane was washed with Trisbuffered saline containing 1% Tween-20 and incubated for 1 hour at room temperature in 5% skim milk with HRP-conjugated secondary antibody (Santa cruz). After incubation, the membrane was treated with ECL substrate (Thermo scientific). The target protein bands were then imaged using a Chemidoc instrument (Bio-rad). The western blot bands were quantified by densitometry using the ImageJ software and CTGF protein expression was normalized by loading control expression.
In vivo study
All animal studies were performed in compliance with the policies of the Sungkyunkwan University Animal Care and Use Committee. SD rats (males, 6-8weeks old) were purchased from Orient Bio (Korea). The rats were anaesthetized prior to cp-asiCTGF treatment with 30 mg/kg of intramuscular Zoletil and 10 mg/kg of intramuscular Rompun. A total dose of 0.1, 0.4, 0.7, or 1 mg of siRNA dissolved in saline solution per injection was administered in a total volume of 100 µl (from a stock solution of 10 mg/ml). For mRNA level analysis, injection site skin at 24 hours after treatment was isolated and subjected to qRT-PCR. For protein level analysis, injection site skin at 72 hours after treatment was isolated and subjected to western blot analysis.
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Rat excision wound model study
The rats were anaesthetized prior to creation of the wounds or with 30 mg/kg of intramuscular Zoletil and 10 mg/kg of intramuscular Rompun. The dorsal skin was punctured to create an excision wound with a width of 8 mm (circular area = 50 mm 2 ) using a disposable biopsy punch. 14 days after treatment, the subjects were divided into three groups (n = 5). Group 1 animals were injected with saline (vehicle only control). Group 2 animals were injected with cp-asiCTGF and Group 3 animals were injected with SC cp-asiCTGF (cp-asiRNA with a scrambled sequence used as the negative control) every 4 days. Total dose of 1.5 mg of siRNA in dissolved in 150 µl saline solution was administered. In detail, 50 µl volume of each siRNA containing solution was injected intradermally at three different positions around excision site. The skin was injected 4 times (Day 14, 18, 22, and 26 ) and analyzed 29 days after initial excision wound treatment.
Confocal microscopy analysis of fluorescent labeled cp-asiRNA
Cy5.5 labeled cp-asiRNA was administered to rat skin by intradermal injection. The skin from the biopsy was embedded in O.C.T compound (Tissue-Tek, Torrance, CA) and frozen in dry ice.
Vertical cross sections (20 µm) were prepared and stained with 4,6-diamidino-2-phenylindole (Sigma). After DAPI staining, the tissue was mounted with Fluorescence Mounting Media (Dacko). Tissue sections were imaged with a red fluorescent filter set in Leica TCS SP8. To increase the effective resolution of the Fluorescence image, 5 images were taken at each z-step, and these 5 image sets were averaged to produce z-step-averaged images, resulting in the final image stack.
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A C C E P T E D ACCEPTED MANUSCRIPT examine the expression levels of CTGF and Collagen type I according to the manufacturer's instructions. Briefly, after deparaffinization and rehydration, the slides were incubated in 3% hydrogen peroxide/methanol to quench endogenous peroxidase. Slides were then incubated in hot Epitope retrieval buffer (provided in kit) to recover epitopes for 20 min at 98°C. Non-specific reactions were blocked by incubating the sections with blocking reagent (included in the kit) for 30 min at room temperature, then 100 µl of CTGF antibody (dilution 1∶100, anti-rabbit, Novus) or 100 µl of collagen type I antibody (dilution 1∶100, anti-rabbit, Thermo scientific) was applied to each slide and incubated overnight at 4°C. Slides were then incubated with working anti-rabbit IHC antibody (provided in kit), and peroxidase activity was visualized with working 3, 3′diaminobenzidine (DAB) substrate (provided in kit). Counterstaining was performed with hematoxylin. Quantitative analysis of stained sections was performed using Image Gauge 4.0 (Fuji Photo Film co., Tokyo, Japan). In this study, immune-positive areas were measured in each region of interest (ROI) using a grid and their proportion among the total stained section was analyzed.
Skin tissue sections were obtained and stained with Masson's Trichrome Stain (MTS) and toluidine blue by KCFC pathology laboratory (Korea, Seoul). The slides stained with Masson's trichrome stain were examined using slide scanner and with the aid of ImageJ software, measurements were made at the intensity of blue color which represent the collage density.
Collagen density was measured under the wound area compared to normal dermis. For each group, the mean of the collagen density under wound area was expressed in the ratio of percentage compared to collagen density of normal dermis (Suvik and Effendy, 2012) .
Statistical analysis
Statistical significance was assessed by Student's t-test.
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